Laugsand Lars E, Ix Joachim H, Bartz Traci M, Djousse Luc, Kizer Jorge R, Tracy Russell P, Dehghan Abbas, Rexrode Kathryn, Lopez Oscar L, Rimm Eric B, Siscovick David S, O'Donnell Christopher J, Newman Anne, Mukamal Kenneth J, Jensen Majken K
Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA; Divisions of Nephrology and Preventive Medicine, University of California San Diego, San Diego, CA, USA.
Atherosclerosis. 2015 Nov;243(1):44-52. doi: 10.1016/j.atherosclerosis.2015.08.031. Epub 2015 Sep 5.
Fetuin-A has a plausible role in the inhibition of arterial calcification, but its association with risk of coronary heart disease (CHD) in the general population is unclear. We used two common genetic variants in the fetuin-A gene (AHSG) that are strongly associated with circulating fetuin-A levels to investigate the associations with risk of CHD and subclinical cardiovascular measures (intima-media thickness, ankle-arm index, and coronary artery calcification).
Genetic variation and fetuin-A levels were assessed in 3299 community-living individuals (2733 Caucasians and 566 African Americans) 65 years of age or older, free of previous cardiovascular disease, who participated in the Cardiovascular Health Study (CHS) in 1992-1993.
Among Caucasians, both rs2248690 and rs4917 were associated with 12% lower fetuin-A concentrations per minor allele (P < 0.0001). The hazard ratios (HRs) per minor allele for incident CHD were 1.12 (95% CI: 1.00-1.26) for rs2248690 and 1.02 (0.91-1.14) for rs4917. Using both genotypes as an instrumental variable for measured fetuin-A, the HRs for one standard deviation increase in genetically determined fetuin-A levels on CHD risk were 0.84 (95% CI: 0.70-1.00) for rs2248690 and 0.97 (95% CI: 0.82-1.14) for rs4917, respectively. However, in CHS neither of the genotypes were associated with subclinical cardiovascular measures and when CHS data were meta-analyzed with data from six other prospective studies (totaling 26,702 Caucasian participants and 3295 CHD cases), the meta-analyzed HRs for incident CHD were 1.12 (0.93-1.34) and 1.06 (0.93-1.20) for rs2248690 and rs4917, respectively (p heterogeneity 0.005 and 0.0048).
Common variants in the AHSG gene are strongly associated with fetuin-A levels, but their concurrent association with CHD risk in current prospective studies is inconsistent. Further investigation in studies with measured fetuin-A and AHSG variants is needed to clarify the potential causal association of fetuin-A with CHD risk.
胎球蛋白-A在抑制动脉钙化方面可能发挥作用,但其与普通人群冠心病(CHD)风险的关联尚不清楚。我们利用胎球蛋白-A基因(AHSG)中两个与循环胎球蛋白-A水平密切相关的常见基因变异,来研究其与冠心病风险及亚临床心血管指标(内膜中层厚度、踝臂指数和冠状动脉钙化)之间的关联。
对3299名65岁及以上、既往无心血管疾病的社区居民(2733名白种人和566名非裔美国人)进行基因变异和胎球蛋白-A水平评估,这些人于1992 - 1993年参与了心血管健康研究(CHS)。
在白种人中,rs2248690和rs4917这两个基因变异每携带一个次要等位基因,胎球蛋白-A浓度均降低12%(P < 0.0001)。rs2248690和rs4917每携带一个次要等位基因发生冠心病的风险比(HRs)分别为1.12(95%CI:1.00 - 1.26)和1.02(0.91 - 1.14)。将这两种基因型作为测量的胎球蛋白-A的工具变量,rs2248690和rs4917基因决定的胎球蛋白-A水平每增加一个标准差,冠心病风险的HRs分别为0.84(95%CI:0.70 - 1.00)和0.97(95%CI:0.82 - 1.14)。然而,在心血管健康研究中,这两种基因型均与亚临床心血管指标无关。当将心血管健康研究的数据与其他六项前瞻性研究的数据(共26702名白种人参与者和3295例冠心病病例)进行荟萃分析时,rs2248690和rs4917发生冠心病的荟萃分析HRs分别为1.12(0.93 - 1.34)和1.06(0.93 - 1.20)(p异质性分别为0.005和0.0048)。
AHSG基因的常见变异与胎球蛋白-A水平密切相关,但在当前的前瞻性研究中,它们与冠心病风险的关联并不一致。需要在对胎球蛋白-A和AHSG变异进行测量的研究中进一步调查,以阐明胎球蛋白-A与冠心病风险之间潜在的因果关系。